Hansa Biopharma CEO to Discuss Scaling Nordic Biotechs at LSX Nordic Congress

The latest announcement is out from Hansa Biopharma AB ( (SE:HNSA) ).

Hansa Biopharma’s CEO Renée Aguiar-Lucander will join a high-profile panel at the LSX Nordic Congress in Copenhagen, discussing “Scaling Success: Key Drivers for Growing Nordic Biotechs” on May 19 at 13:10 CET. The session, moderated by Alligator Biosciences CEO Søren Bregenholt and featuring leaders from DANSK BIOTEK, BOOST Pharma, Freya Biosciences and BII, underscores Hansa’s role in the Nordic biotech ecosystem and highlights its positioning as a growth-focused player in advanced immunomodulatory therapies.

Participation in this forum allows Hansa Biopharma to showcase its strategic vision, technology platform and commercial-stage assets to investors and industry peers. The company’s involvement in a discussion on scaling Nordic biotechs may help reinforce its visibility in key European and U.S. markets, support stakeholder confidence and signal its ambition to expand operations in high-need therapeutic areas such as transplantation and autoimmune diseases.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK103.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

More about Hansa Biopharma AB

Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing novel immunomodulatory therapies for acute and complex immune disorders. Its proprietary IgG-cleaving enzyme technology targets serious unmet medical needs in transplantation, gene therapy and autoimmune diseases, with key assets including imlifidase and next-generation molecule HNSA-5487.

Average Trading Volume: 354,427

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK3.02B

For detailed information about HNSA stock, go to TipRanks’ Stock Analysis page.